Conventional and immunity-modulating treatment in chronic inflammatory bowel disease;Konventionelle und immunmodulatorische therapie bei chronisch- entzundlichen darmerkrankungen

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 40, 1999, Pages 1173-1177

  Marth, Th ^a   Zeitz, Martin ^a   Hohlfeld, München R ^a   Kabelitz, Kiel D ^a   Kremer, Kiel B ^a   Lode, Berlin H ^a   Meinertz, Hamburg T ^a   Philipp, Essen Th ^a   Sauerbruch, Bonn T ^a   Werdan, Halle K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CD4 ANTIGEN; CYCLOSPORIN; GLUCOCORTICOID; INTERLEUKIN 10; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG HYPERSENSITIVITY; ENDOSCOPY; ENTERITIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; ORAL DRUG ADMINISTRATION; PANCREATITIS; ULCERATIVE COLITIS;

EID: 0033536630     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024510     Document Type: Article

References (15)

1. 1 Baert, F. J., G. R. D'Haens, M. Peeters, M. I. Hiele, T. F Schaible, D. Shealy, K. Geboes, P. J. Rutgeerts: Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116 (1999), 22.
2. 2 Cuffari, C., Y. Theoret, S. Latour, G. Seidman: 6-mercaptopurin metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39 (1996), 401.
3. 3 Curran, M. E., K. F. Lau, J. Hampe, S. Schreiber, S. Bridger, A. J. Macpherson, L. R. Cardon, H. Sakul, T. J. Harris, P. Stokkers, S. J. Van Deventer, M. Mirza, A. Raedler, W. Kruis, U. Meckler, D. Theuer, T. Herrmann, P. Gionchetti, J. Lee, C. Mathew, J. Lennard-Jones: Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 115 (1998), 1066.
4. 4 Elson, C. O.: The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100 (1996), 656.
5. 5 Fleig, W. E.: Konservative Behandlungsstrategien bei chronischentzündlichen Darmerkrankungen. Internist (Berlin) 39 (1998), 1030.
6. 6 Kruis, W., C. Pohl: Rezidiv-verhütende (remissionserhaltende) Therapie bei chronisch-entzündlichen Darmerkrankungen. Dtsch. Med. Wschr. 123 (1998), 85.
7. 7 Lochs, H., G. Adler, C. Beglinger, R. Duchmann, J. Emmrich, K. Ewe, A. Gangl, C. Gasche, E. Hahn, P. Hoffmann, B. Kaskas, H. Malchow, C. Pohl, A. Raedler, E. Renner, J. Schölmerich, S. Schreiber, E. Stange, H. Tilg, H. Vogelsang, N. Weigert, M. Zeitz: Anti-TNF-Antikörpertherapie bei Morbus Crohn - Stellungnahme und Empfehlungen einer internationalen Expertengruppe. Z. Gastroenterol. 37(1999), 509.
8. 8 Modigliani, R.: Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Inflamm. Bowel Dis. 4 (1998), 244.
9. 9 Neurath, M.F., R. Wanitschke, M. Peters, F. Krummenauer, K.H. Meyer zum Büschenfelde, J.F. Schlaak. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44(1999), 625.
10. 10 Pearson, D. C., G. R. May, G. H. Fick, L. R. Sutherland: Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 123 (1995), 132.
11. 11 Sandborn, W. J., E. C. Van O, B. J. Zins, W. J. Tremaine, D. C. Mays, J. J. Lipsky: An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology, 109 (1995), 1808.
12. 12 Stange, E. F., S. Schreiber, A. Raedler, A. Stallmach, J. Schölmerich, K. Loeschke, M. Starlinger, W. Fischbach, W.F. Caspary: Therapie des Morbus Crohn - Ergebnisse einer Konsuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen. Z. Gastroenterol. 35 (1997), 541.
13. 13 Targan, S. R., S. B. Hanauer, S. J. Van Deventer, L. Mayer, D. H. Present, T. Braakman, K. L. DeWoody, T. F. Schaible, P. J. Rutgeerts: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New Engl. J. Med. 337 (1997), 1029.
14. 14 Van Deventer, S. J., C. O. Elson, R. N. Fedorak for the Crohn's Disease Study Group: Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 113 (1997), 383.
15. 15 Zeitz, M.: Conventional drug therapy and immunomodulatory strategies in IBD. In Stallmach, A., M. Zeitz, W. Strober, T. T. MacDonald, H. Lochs (Ed.): Induction and Modulation of Gastrointestinal Inflammation (Kluwer Academic Publishers: Dordrecht 1999), 251.